{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:41:29Z","timestamp":1782780089920,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005744","name":"Lastentautien Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Evaluation of costs and short-term cost-effectiveness of infliximab plus methotrexate (IFX\u2009+\u2009MTX); triple therapy of hydroxychloquine, sulphasalazine, and methotrexate (TRIPLE); or methotrexate monotherapy (MTX) in patients with new-onset polyarticular juvenile idiopathic arthritis (JIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a prospective multicenter study (ACUTE-JIA), costs and health outcomes of 60 randomized patients with new-onset disease-modifying anti-rheumatic drug (DMARD)-na\u00efve polyarticular JIA were analyzed during the first year. A mapping algorithm was used to obtain utility values from Child Health Assessment Questionnaire (CHAQ). Wallace criteriae were used to assess clinically inactive disease (CID). Linear regression with non-parametric bootstrapping was used to adjust imbalances at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using prices for IFX biosimilar, adjusted annual mean (SD) costs of treatment (\u20ac) were 21,164 (4158), 12,136 (5286), and 18,300 (8635) on IFX\u2009+\u2009MTX, TRIPLE, and MTX, respectively. Incremental cost-effectiveness ratio (ICER) for IFX\u2009+\u2009MTX as compared with TRIPLE or MTX were 3442 \u20ac or 678 \u20ac per additional month spent in CID. Mean (SD) quality-adjusted life years (QALYs) for IFX\u2009+\u2009MTX, TRIPLE and MTX were 0.755 (0.065), 0.725 (0.062), and 0.686 (0.124). ICER for IFX\u2009+\u2009MTX vs TRIPLE was 294,433 \u20ac, and for IFX\u2009+\u2009MTX vs MTX 31,435 \u20ac per QALY gained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In short-term, biosimilar IFX\u2009+\u2009MTX can be considered cost-effective when compared with MTX alone. TRIPLE was cost-effective when compared with MTX and showed cost advantage when compared with IFX\u2009+\u2009MTX. Cost per time spent in CID showed similar results than ICER evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>This trial was primarily registered with the Ethical Board of Helsinki District University Hospital (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.hus.fi\">https:\/\/www.hus.fi<\/jats:ext-link>), clinical trial number 211864, and later with ClinicalTrials.gov, number NCT01015547.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-022-00748-w","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:02:36Z","timestamp":1668639756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-5349","authenticated-orcid":false,"given":"Maarit","family":"Tarkiainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirjo","family":"Tynj\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"V\u00e4h\u00e4salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Aalto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katariina","family":"Rebane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Lahdenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"748_CR1","first-page":"2275","volume":"30","author":"L Berntson","year":"2003","unstructured":"Berntson L, Andersson Gare B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al. Incidence of juvenile idiopathic arthritis in the nordic countries. A population-based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30:2275\u201382.","journal-title":"J Rheumatol"},{"key":"748_CR2","first-page":"507","volume":"4","author":"M Glerup","year":"2019","unstructured":"Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic juvenile idiopathic arthritis (JIA) cohort. Arthritis Care Res (Hoboken). 2019;4:507\u201316.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"748_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71:846\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"748_CR4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/rheumatology\/keq432","volume":"50","author":"F Prince","year":"2011","unstructured":"Prince F, Bekker-Grob EW, Twilt M, Van Rossum M, Hoppenreijs E, Ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology. 2011;50:1131\u20136.","journal-title":"Rheumatology"},{"key":"748_CR5","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/annrheumdis-2013-205060","volume":"74","author":"J Eriksson","year":"2015","unstructured":"Eriksson J, Karlsson J, Bratt J, Petersson I, Van Vollenhoven R, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015;74:1094\u2013101.","journal-title":"Ann Rheum Dis"},{"key":"748_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/M16-0713","volume":"167","author":"N Bansback","year":"2017","unstructured":"Bansback N, Phibbs C, Sun H, O\u2019Dell J, Brophy M, Keystone E, et al. Triple therapy versus biologic therapy for active rheumatoid arthritis. Ann Intern Med. 2017;167:8\u201316.","journal-title":"Ann Intern Med"},{"key":"748_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","volume":"46","author":"G Amarilyo","year":"2016","unstructured":"Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope T, Woo J, et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46:312\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"748_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2011","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M, Kr\u00f6ger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early Polyarticular juvenile idiopathic arthritis (ACUTE\u2013JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"748_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"D Lovell","year":"2008","unstructured":"Lovell D, Reiff A, Ilowite N, Wallace C, Chon Y, Lin S, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496\u2013504.","journal-title":"Arthritis Rheum"},{"key":"748_CR10","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"C Wallace","year":"2012","unstructured":"Wallace C, Giannini E, Spalding S, Hashkes P, O\u2019Neil K, Zeft A, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012\u201321.","journal-title":"Arthritis Rheum"},{"key":"748_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R, Feldman B, Laxer R. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2011;63:111\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"748_CR12","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/acr.22903","volume":"68","author":"NJ Luca","year":"2016","unstructured":"Luca NJ, Burnett HF, Ungar WJ, Feldman B, Laxer R. Cost-effectiveness analysis of first-line treatment with biologic agents in Polyarticular juvenile idiopathic arthritis. Arth Care Res. 2016;68:1803\u201311.","journal-title":"Arth Care Res"},{"key":"748_CR13","unstructured":"Finnish Tax Administration. Kilometre and per diem allowances. (www.vero.fi\/en\/individuals\/vehicles\/kilometre_and_per_diem_allowances\/) Accessed 23 March 2022."},{"key":"748_CR14","unstructured":"Finnish Institute for Health and Welfare. Unit prices for Health and social care. (http:\/\/urn.fi\/URN:ISBN:978-952-302-079-5) Accessed 23 March 2022."},{"key":"748_CR15","unstructured":"Helsinki University Central Hospital. Price list for services. (http:\/\/www.hus.fi\/hus-tietoa\/talous\/Hinnoittelu\/Documents\/HUS%20Palveluhinnasto%202016,%20osa%202%20Suoriteperusteiset%20hinnat.pdf) Accessed 23 March 2022."},{"key":"748_CR16","unstructured":"Official Statistics of Finland (OSF). Price index of public expenditure [e-publication]. Helsinki: Statistics Finland. (https:\/\/www.stat.fi\/til\/jmhi\/index_en.html) Accessed 23 March 2022."},{"key":"748_CR17","first-page":"2020","volume":"31","author":"C Wallace","year":"2004","unstructured":"Wallace C, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2020.","journal-title":"J Rheumatol"},{"key":"748_CR18","volume-title":"Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (HUMIRA)[abstract]","author":"R Boggs","year":"2002","unstructured":"Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (HUMIRA)[abstract]: International Society of Pharmacoeconomics and Outcomes Research; 2002. abstract UT3. (https:\/\/core.ac.uk\/download\/pdf\/82302362.pdf) Accessed 23 March 2022"},{"key":"748_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","volume":"11","author":"G Barton","year":"2008","unstructured":"Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11:886\u201397.","journal-title":"Value Health"},{"key":"748_CR20","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods [PMG9] (https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword) Accessed 18 Nov 2020."},{"key":"748_CR21","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","volume":"353","author":"T Mottonen","year":"1999","unstructured":"Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353:1568\u201373.","journal-title":"Lancet"},{"key":"748_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715.","journal-title":"Ann Rheum Dis"},{"key":"748_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78:51\u20139.","journal-title":"Ann Rheum Dis"},{"key":"748_CR24","doi-asserted-by":"publisher","unstructured":"Kuhlmann A, Schmidt T, Treskova M, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, et al. Social\/economic costs and health-related quality of life. Eur J Health Econ. 2016;(Suppl1):79\u201387. https:\/\/doi.org\/10.1007\/s10198-016-0786-1.","DOI":"10.1007\/s10198-016-0786-1"},{"issue":"10086","key":"748_CR25","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm E, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator nfliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"key":"748_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2017-211968","volume":"77","author":"J Klotsche","year":"2018","unstructured":"Klotsche J, Minden K, Niewerth M, Horneff G. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis. 2018;77:996\u20131002.","journal-title":"Ann Rheum Dis"},{"key":"748_CR27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/acr.20069","volume":"62","author":"HM Albers","year":"2010","unstructured":"Albers HM, Brinkman DMC, Kamphuis SSM, Van Suijlekom-Smit LWA, Van Rossum MAJ, Hoppenreijs E, et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res. 2010;62:204\u201312.","journal-title":"Arthritis Care Res"},{"key":"748_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/ard.2007.073445","volume":"67","author":"M Bartoli","year":"2008","unstructured":"Bartoli M, Tar\u00f2 M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:370\u20134.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00748-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T04:28:52Z","timestamp":1701404932000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00748-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00748-w","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was primarily registered with the Ethical Board of Helsinki District University Hospital (), clinical trial number 211 864, and later with ClinicalTrials.gov, number NCT01015547. A written informed consent was obtained from the patients or their families.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PV reports non-financial support from Abbvie, and Novartis; personal fees and non-financial support from Pfizer, MSD, Sobi, and Roche, outside the submitted work; JM is a founding partner of ESiOR Oy and a board member of Siltana Oy. These companies were not involved in carrying out this research. Other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}